Sarita Prabhakaran

Dr. Sarita Prabhakaran

College of Medicine and Public Health, Flinders University, Adelaide, Australia
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Human Pathology
Verified
Journal Article
Closed access
SPSarita Prabhakaran
Sarita Prabhakaran
AHAshleigh Hocking
Ashleigh Hocking
CKChankyung Kim
Chankyung Kim
MHMatthew Hussey
Matthew Hussey
SKSonja Klebe
Sonja Klebe

20 August 2022 in Pathology
Verified
Journal Article
Open access
CMCarmela Martini
Carmela Martini
JLJessica M Logan
Jessica M Logan
ASAlexandra Sorvina
Alexandra Sorvina
CGColin Gordon
Colin Gordon
ABAndrew R Beck
Andrew R Beck
Doug BrooksDoug Brooks
Doug Brooks
Diagnosis and assessment of patients with prostate cancer is dependent on accurate interpretation and grading of histopathology. However, morphology does not necessarily reflect the complex biological changes occur-ring in prostate cancer disease progression, and current biomarkers have demonstrated limited clinical utility in patient assessment. This study aimed to develop bio-markers that accurately define prostate cancer biology by distinguishing specific pathological features that enable reliable interpretation of pathology for accurate Gleason grading of patients. Online gene expression databases were interrogated and a pathogenic pathway for prostate cancer was identified. The protein expression of key genes in the pathway, including adaptor protein containing a pleckstrin homology (PH) domain, phosphotyrosine-binding (PTB) domain, and leucine zipper motif 1 (Appl1), Sortilin and Syndecan-1, was examined by immunohistochemistry (IHC) in a pilot study of 29 patients with prostate cancer, using monoclonal antibodies designed against unique epitopes. Appl1, Sortilin, and Syndecan-1 expression was first assessed in a tissue microarray cohort of 112 patient samples, demonstrating that the monoclonal antibodies clearly illustrate gland morphologies. To determine the impact of a novel IHC-assisted interpretation (the utility of Appl1, Sortilin, and Syndecan-1 labelling as a panel) of Gleason grading, versus standard haematoxylin and eosin (H&E) Gleason grade assignment, a radical prostatectomy sample cohort comprising 114 patients was assessed. In comparison to H&E, the utility of the biomarker panel reduced subjectivity in interpretation of prostate cancer tissue morphology and improved the reliability of pathology assessment, resulting in Gleason grade redistribution for 41% of patient samples. Importantly, for equivocal IHC-assisted labelling and H&E staining results, the cancer morphology interpretation could be more accurately applied upon re-review of the H&E tissue sections. This study addresses a key issue in the field of prostate cancer pathology by presenting a novel combination of three biomarkers and has the po-tential to transform clinical pathology practice by stand-ardising the interpretation of the tissue morphology.

15 April 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
KWKaren Walker-Bone
Karen Walker-Bone
MGMelissa A. Goodwin
Melissa A. Goodwin
BBBrent Bufton
Brent Bufton
BDBrett Andrew Davis
Brett Andrew Davis
HWHenry Wong
Henry Wong
TDTim Driscoll
Tim Driscoll
Background: The use of asbestos-containing products was banned in Australia in 2003. However, the rates of new cases of mesothelioma, which has a very long latent period between exposure and disease, have continued to increase. The aim of this study was to investigate mesothelioma incidence in Australia by year of birth and age–period–cohort analysis and to develop projections of expected mesothelioma cases until 2034. Methods: Data were derived from the Australian Cancer Database which provides complete national records of mesothelioma cases notified between 1982 and 2020. Incidence rates were age-standardized to the 2001 Australian standard population to enable comparisons of the population across time. Age–period–cohort models were used to examine the temporal trends of incidence rates by age, calendar year, and birth cohort. Projections for incidence rates of mesothelioma for 2020 to 2034 were estimated using Nordpred models. Results: Graphs of age-standardized incidence rates of mesothelioma suggest a birth cohort effect, and the age–period–cohort model confirmed this. There was a birth cohort effect in all cohorts born before 1960, strongest in cohorts born during 1920 to 1949. Projection modeling to 2034 suggested that the age-standardized rates will continue to decline whereas crude incidence rates of mesothelioma will stabilize and then gradually decline, mostly among people of 60 to 84 years of age. Conclusions: The findings are consistent with the greatest risk of mesothelioma in Australia occurring in cohorts with the highest levels of historical cumulative occupational exposure, showing the value of a ban on asbestos. Impact: The number of new cases of mesothelioma per year is not expected to decline until after 2030.

21 June 2023 in Pathology
Verified
Journal Article
Open access
ASAlexandra Sorvina
Alexandra Sorvina
CMCarmela Martini
Carmela Martini
SPSarita Prabhakaran
Sarita Prabhakaran
JLJessica M. Logan
Jessica M. Logan
BUBenjamin Ung
Benjamin Ung
Doug BrooksDoug Brooks
Doug Brooks
The presence of intraductal carcinoma of the prostate (IDCP) correlates with late-stage disease and poor outcomes for patients with prostatic adenocarcinoma, but the accurate and reliable staging of disease severity remains challenging. Immunohistochemistry (IHC) has been utilised to overcome problems in assessing IDCP morphology, but the current markers have only demonstrated limited utility in characterising the complex biology of this lesion. In a retrospective study of a cohort of patients who had been diagnosed with IDCP, we utilised IHC on radical prostatectomy sections with a biomarker panel of Appl1, Sortilin and Syndecan-1, to interpret different architectural patterns and to explore the theory that IDCP occurs from retrograde spread of high-grade invasive prostatic adenocarcinoma. Cribriform IDCP displayed strong Appl1, Sortilin and Syndecan-1 labelling patterns, while solid IDCP architecture had high intensity Appl1 and Syndecan-1 labelling, but minimal Sortilin labelling. Notably, the expression pattern of the biomarker panel in regions of IDCP was similar to that of adjacent invasive prostatic adenocarcinoma, and also comparable to prostate cancer showing perineural and vascular invasion. The Appl1, Sortilin, and Syndecan-1 biomarker panel in IDCP provides evidence for the model of retrograde spread of invasive prostatic carcinoma into ducts/acini, and supports the inclusion of IDCP into the five-tier Gleason grading system.

1 October 2018 in Pathology
Verified
Journal Article
Closed access
SKSonja Klebe
Sonja Klebe
SPSarita Prabhakaran
Sarita Prabhakaran
AHAshleigh Hocking
Ashleigh Hocking
EPEmily Pulford
Emily Pulford
SMSarah Moore
Sarah Moore
DHDouglas W. Henderson
Douglas W. Henderson

16 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JLJessica M Logan
Jessica M Logan
AHAshley Hopkins
Ashley Hopkins
CMCarmela Martini
Carmela Martini
Alexandra SorvinaAlexandra Sorvina
Alexandra Sorvina
PTPrerna Tewari
Prerna Tewari
Doug BrooksDoug Brooks
Doug Brooks
Gleason scoring is used within a five-tier risk stratification system to guide therapeutic decisions for patients with prostate cancer. This study aimed to compare the predictive performance of routine H&E or biomarker-assisted ISUP (International Society of Urological Pathology) grade grouping for assessing the risk of biochemical recurrence (BCR) and clinical recurrence (CR) in patients with prostate cancer. This retrospective study was an assessment of 114 men with prostate cancer who provided radical prostatectomy samples to the Australian Prostate Cancer Bioresource between 2006 and 2014. The prediction of CR was the primary outcome (median time to CR 79.8 months), and BCR was assessed as a secondary outcome (median time to BCR 41.7 months). The associations of (1) H&E ISUP grade groups and (2) modified ISUP grade groups informed by the Appl1, Sortilin and Syndecan-1 immunohistochemistry (IHC) labelling were modelled with BCR and CR using Cox proportional hazard approaches. IHC-assisted grading was more predictive than H&E for BCR (C-statistic 0.63 vs. 0.59) and CR (C-statistic 0.71 vs. 0.66). On adjusted analysis, IHC-assisted ISUP grading was independently associated with both outcome measures. IHC-assisted ISUP grading using the biomarker panel was an independent predictor of individual BCR and CR. Prospective studies are needed to further validate this biomarker technology and to define BCR and CR associations in real-world cohorts.